Alterity Therapeutics (ATHE) Stock Price, News & Analysis

Company Overview

Alterity Therapeutics Limited (NASDAQ: ATHE) is an Australia-based clinical-stage biotechnology company developing treatments for neurodegenerative diseases. Its research focuses on abnormal protein misfolding and aggregation, biological processes associated with disorders such as multiple system atrophy and Parkinson’s disease.

The company’s lead drug candidate, ATH-434, is an orally administered small molecule designed to cross the blood-brain barrier and inhibit the aggregation of alpha-synuclein, a protein implicated in several neurodegenerative conditions. Alterity has evaluated ATH-434 in clinical studies involving patients with multiple system atrophy and is also investigating its potential application in Parkinson’s disease and related disorders.

Alterity was formerly known as Prana Biotechnology and adopted its current name in 2018. The company conducts its research and development activities in Australia and the United States and is led by Chief Executive Officer David Stamler. Its shares trade on the Nasdaq Capital Market under the symbol ATHE and on the Australian Securities Exchange under the symbol ATH.

Key Stats

• Today's Range: $3.41 to $3.89
• 50-Day Range: $3.50 to $4.91
• 52-Week Range: $2.66 to $5.89
• Volume: 21,410 shs
• Average Volume: 25,870 shs
• Market Capitalization: $66.36 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Moderate Buy

Alterity Therapeutics Stock Analysis - MarketRank™

Alterity Therapeutics scored higher than 81% of companies evaluated by MarketBeat, and ranked 98th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Alterity Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Alterity Therapeutics has a consensus price target of $10.00, representing about 173.2% upside from its current price of $3.66.

Amount of Analyst Coverage

Alterity Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Earnings Growth

Earnings for Alterity Therapeutics are expected to remain at ($0.12) per share in the coming year.

Price to Book Value per Share Ratio

Alterity Therapeutics has a P/B Ratio of 2.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.23% of the float of Alterity Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Alterity Therapeutics has a short interest ratio ("days to cover") of 1.29, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Alterity Therapeutics has recently decreased by 18.42%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alterity Therapeutics does not currently pay a dividend.

Dividend Growth

Alterity Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.88

News Sentiment

Alterity Therapeutics has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Alterity Therapeutics this week, compared to 2 articles on an average week.

Company Ownership

• Score: 3.6 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $23,810.00 in company stock, which represents 0.0359% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Alterity Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $23,810.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

38.80% of the stock of Alterity Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

2.14% of the stock of Alterity Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 7/30/2026
• Today: 9/29/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ATHE
• CIK: 1131343
• Web: www.alteritytherapeutics.com
• Phone: (139) 349-4906
• Fax: 61-3-9348-0377
• Employees: 11
• Year Founded: 1997

Price Target and Rating

• Average Price Target for Alterity Therapeutics: $10.00
• High Price Target: $16.00
• Low Price Target: $2.00
• Potential Upside/Downside: +173.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.57
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.52
• Quick Ratio: 14.52

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.60 per share
• Price / Book: 2.29

Miscellaneous

• Outstanding Shares: 18,130,000
• Free Float: 11,093,000
• Market Cap: $66.36 million
• Optionable: Not Optionable
• Beta: 0.27